Staar Surgical 2026 Stifel Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay, great. Good morning, everyone. Tom Stephan, Stifel Research. Really excited to have STAAR Surgical here at the conference this year. Warren, Deborah, thank you guys so much for joining.
Of course. I am going to dive right in, 30 minutes, a lot of questions I want to try to get to.
Warren, I will start off on China trends. In-market ICL shipments year to date, you noted on the call, up a little over 12%, an acceleration from full year 2025, up mid-single digits. Very encouraging. To kick things off, Warren, can you elaborate a bit more on the ICL demand picture in China and what you are seeing on the ground from a volume standpoint?
Sure. First of all, thanks for having us. Great conference. Good to see everybody. Look, we are excited about, and it is tepid excitement because you think about the China market and the way the economy has been challenged each of the last couple of years. Starting in 2023, we saw a pretty sharp decline. That same metric around ICL volume shipments in that time period was down about 14.5% by our numbers. 2025 was up 6%. The 12.5% needs to be put in context. Again, that is just volume shipments, but it is more closely a proxy for what we believe is happening because as inventory levels have come down from 2023, we had far too much inventory in the country. Now Deborah and I have a real commitment. We look at it on a weekly basis.
Inventory is very healthy now, healthy in a good way from a low volume of inventory, just enough for service levels. I think that speaks to the refractive market in China, which is pretty widely publicized as probably flat if you listen to Zeiss and if you listen to Aier and Bright Eye and Huaxia and all the public reporting that goes on. The market's flat and folks are taking advantage of the higher average selling price products. You see Aier say they've moved a higher percentage of their procedural mix to higher priced products, Toric being one, EVO+ being another, I think the most notable, which is why we feel we're in a position of taking share and also having a little better than market performance.
Got it. That's great. On the call, you noted that 3Q in-market shipments were even higher than that 12% plus year-to-date figure. It sounds like summer high season, from an in-market shipment standpoint, finished strong for you in the third quarter. 4Q is seasonally weaker in China, but from a year-over-year standpoint, I guess for the fourth quarter, what factors are most important that we should be considering in assessing, I'll call it the sustainability of recent trends?
Sure. Q3, we are trying to provide as much transparency as we can. The data that we use to manage the business is the data that we're providing. When we say that those are the in-market shipments, that's distributor numbers that they report to us. Looking at them on a quarterly basis, which is why we didn't give the quarter because it's kind of an eye-popping number. The reality is the underlying in-market volume's pretty good for us right now. To your question, how does that apply to Q4? Q4 last year was pretty soft for a bunch of reasons. We've said we believe we're going to grow bigger than what we had Q4 last year. When you think about advantages that we have this Q4 that we didn't have last Q4, mix is a big piece of that.
When we say price, what we really mean is mix. It's average selling price based on percentage of V5, which is growing, and percentage of Toric procedures. Does everyone know what a Toric is? When you have an astigmatism, many of us do, probably half the population does. When you put an ICL in, a monofocal ICL essentially is for a patient with an eye that is shaped like a basketball. Think of it that way. When you have an astigmatism, your eye is getting more and more shaped just slightly like a football, which means that the steep axis on your eye is slightly different than the steep axis on my eye. We're willing to manufacture all the way 360 degrees to that steep axis as a custom lens for a patient, which is different than most of our competitors.
Even the ones that provide a Toric typically do it only on a made-to-order. It's a competitive moat for us. The higher the percentage of Toric procedures, the more revenue we get because we charge a premium for that. Mix is higher Toric and higher V5. That's happening in Q4. We already know that. The difference in Q4 versus Q3 is we're going to be able to supply what they need because we were unable to fully supply in Q3. Last year, the same quarter, we didn't have V5 available to the market.
Okay. That's beyond the fact that we're taking share.
I think there's that dynamic that's going to be helpful.
Got it. The supply dynamic I will revisit very shortly. Maybe last one, just on trends. You mentioned the mix of V5 is growing. I think you said exiting 2Q, it was close to a third. Roughly what was the V5 mix in China exiting the third quarter, roughly speaking?
We got scolded a little bit by our distributors and by some of our hospitals because they compete. Remember, price is a component of that. We charge more for these things. The reality is they've asked us, just like share, they've asked us to keep that confidential. What I'll say is we did say exit share at Q2 was 30% V5. That's true. It grew in Q3, so it's more. We're going to see continued adoption of V5 because patients want it. There's no shortage. There's 1.5 billion patients or people in China, and V5 is the first offer that the practices are giving because it's their highest economics. If a patient can't afford it, then they go down to V4 or they go down to a SMILE Pro if the patient's appropriate. We believe it's going to continue.
To the extent that we have a large premium between V5 and V4, I think simple pricing economics would tell you that as long as we're able to charge a premium, we will continue to do that. You do not want, in that scenario, to get all of the patients on V5. I mean, you would want that, but in order to have a premium, you would need to have a difference. The higher the mix comes, the more the price will slightly come down. There will always be a premium until we get to some point distant in the future where it just makes sense financially to stop manufacturing it.
Right. We will be good shareholder capital investors that way and make sure that we titrate that.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
